Prognostic value of serum tumor markers in patients with lung cancer.

Abstract

BACKGROUND:

The role of tumor markers in the diagnosis and prognosis of lung cancer is under investigation.

OBJECTIVES:

The aim of this study was to investigate the diagnostic and prognostic significance of pre-therapeutic levels of various serum tumor markers, CYFRA 21-1, neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), CA 125 and squamous cell carcinoma antigen (SCCAg), in patients with lung cancer.

METHODS:

We studied 102 consecutive patients (mean age 65.2 +/- 11 years) with newly diagnosed lung cancer (96 males, 94%, with a mean age of 66.3 +/-10.5 years). All patients had a 5-year follow-up. Measurements of the serum tumor markers were performed on initial diagnosis.

RESULTS:

Eighty-four patients (82%) had non-small-cell lung cancer (NSCLC) and 18 (18%) small-cell lung cancer (SCLC). From the 84 patients with NSCLC, 34 patients (33%) had squamous-cell lung cancer, 23 (22%) adenocarcinoma and 23 (22%) large-cell carcinomas. The overall median survival was 8.5 months. All SCLC patients had extensive disease with a median survival of 10.1 months and NSCLC patients of 8.4 months. Significant differences in the mean values of NSE and CYFRA 21-1 were observed between SCLC and NSCLC. In NSCLC, CYFRA 21-1, TPA, CA 125 and SCCAg serum levels were related to the stage of the disease at diagnosis, and CYFRA 21-1, NSE, TPA and CA-125 were related to a poor outcome. None of the above tumor markers was related to survival in the SCLC group.

CONCLUSION:

CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. Also, CYFRA 21-1 with TPA and CA 125 may provide useful information regarding the staging of the disease at diagnosis and the prognosis of patients with NSCLC.

• Authors: Kostas D Hatzakis, Marios E Froudarakis, Demosthenes Bouros, Nikolaos Tzanakis, Nikolaos Karkavitsas, Nikolaos M Siafakas
• Journal: Respiration; international review of thoracic diseases (Respiration) Vol. 69 Issue 1 Pg. 25-9 ( 2002) ISSN: 0025-7931 [Print] Switzerland
• PMID: 11844959 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Antigens, Neoplasm
• Biomarkers, Tumor
• CA-125 Antigen
• Carcinoembryonic Antigen
• Keratin-19
• antigen CYFRA21.1
• Keratins
• Phosphopyruvate Hydratase

Topics

• Adenocarcinoma (mortality, pathology, therapy)
• Adult
• Aged
• Aged, 80 and over
• Analysis of Variance
• Antigens, Neoplasm (analysis)
• Biomarkers, Tumor (analysis)
• CA-125 Antigen (analysis)
• Carcinoembryonic Antigen (analysis)
• Carcinoma, Large Cell (mortality, pathology, therapy)
• Carcinoma, Non-Small-Cell Lung (mortality, pathology, therapy)
• Carcinoma, Squamous Cell (mortality, pathology, therapy)
• Female
• Humans
• Keratin-19
• Keratins
• Lung Neoplasms (mortality, pathology, therapy)
• Male
• Middle Aged
• Phosphopyruvate Hydratase (analysis)
• Probability
• Prognosis
• Prospective Studies
• Regression Analysis
• Sensitivity and Specificity
• Survival Analysis